Profile data is unavailable for this security.
About the company
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
- Revenue in DKK (TTM)367.97m
- Net income in DKK-712.00m
- Incorporated1997
- Employees288.00
- LocationZealand Pharma A/SSydmarken 11SOEBORG 2860DenmarkDNK
- Phone+45 88773600
- Fax+45 88773898
- Websitehttps://www.zealandpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Galapagos NV | 2.27bn | 234.97m | 13.44bn | 683.00 | 57.16 | 0.619 | -- | 5.91 | 0.4783 | 4.29 | 4.63 | 44.16 | 0.0692 | 0.442 | 6.01 | 472,080.50 | 0.7149 | -1.48 | 0.7902 | -1.65 | 88.04 | -- | 10.33 | -14.42 | 9.87 | -- | 0.0037 | -- | 3.47 | -2.02 | 94.42 | -- | 7.04 | -- |
BB BIOTECH AG | 2.15bn | 1.86bn | 16.14bn | -- | 8.64 | 0.8444 | -- | 7.52 | 4.26 | 4.26 | 4.95 | 43.52 | 0.1024 | -- | 117.67 | -- | 8.86 | 2.34 | 10.07 | 2.52 | 97.69 | 99.06 | 86.47 | 35.40 | -- | -- | 0.118 | 217.78 | -57.97 | -37.98 | 42.26 | -- | -- | -8.09 |
MorphoSys AG | 1.38bn | -3.44bn | 19.03bn | 446.00 | -- | -- | -- | 13.79 | -12.48 | -12.59 | 5.13 | -8.89 | 0.0962 | 0.7357 | 5.08 | 353,012.10 | -23.99 | -10.25 | -31.72 | -11.61 | 85.74 | 85.92 | -249.51 | -78.53 | 0.7747 | -- | -- | -- | -14.37 | 25.53 | -25.60 | -- | 3.11 | -- |
BACHEM HOLDING AG | 4.58bn | 900.35m | 43.85bn | 2.01k | 48.54 | 4.23 | 34.32 | 9.57 | 1.52 | 1.52 | 7.71 | 17.42 | 0.3585 | 1.06 | 4.33 | 288,020.40 | 7.05 | 8.85 | 8.10 | 10.28 | 31.04 | 31.63 | 19.66 | 19.74 | 1.57 | 100.82 | 0.0002 | 55.37 | 8.57 | 15.37 | 11.10 | 19.12 | 50.88 | 7.78 |
Zealand Pharma A/S | 367.97m | -712.00m | 63.57bn | 288.00 | -- | 6.76 | -- | 172.75 | -11.69 | -11.69 | 6.06 | 132.48 | 0.0603 | 4.88 | 2.30 | 1,454,435.00 | -11.67 | -42.74 | -12.12 | -50.24 | 90.96 | 96.13 | -193.49 | -464.66 | 35.57 | -- | 0.0399 | -- | 229.65 | 55.27 | 27.12 | -- | 42.53 | -- |
Qiagen NV | 13.02bn | 487.73m | 68.62bn | 5.90k | 143.85 | 2.99 | 36.20 | 5.27 | 0.2862 | 0.2862 | 7.81 | 13.78 | 0.3252 | 2.01 | 5.57 | 292,457.30 | 1.22 | 5.41 | 1.47 | 6.53 | 63.03 | 64.65 | 3.75 | 16.35 | 1.46 | -- | 0.2916 | -- | -8.23 | 5.53 | -19.35 | 12.38 | 1.55 | -- |
Genmab A/S | 18.97bn | 5.50bn | 116.44bn | 2.53k | 20.97 | 3.61 | -- | 6.14 | 83.89 | 83.89 | 289.07 | 487.96 | 0.5373 | 13.82 | 3.49 | 8,605,717.00 | 15.59 | 17.43 | 17.13 | 18.59 | 96.83 | -- | 29.01 | 35.87 | 5.02 | -- | 0.0319 | -- | 13.57 | 40.35 | -20.18 | 24.21 | -4.66 | -- |
argenx SE | 10.84bn | -1.37bn | 212.09bn | 1.15k | -- | 7.42 | -- | 19.57 | -3.13 | -3.13 | 24.67 | 64.11 | 0.4043 | 0.6484 | 3.94 | 1,265,533.00 | -5.11 | -17.65 | -5.70 | -19.79 | 89.41 | -- | -12.65 | -97.72 | 7.88 | -- | 0.0079 | -- | 198.56 | 117.25 | 58.42 | -- | 122.32 | -- |
Lonza Group AG | 53.09bn | 4.54bn | 305.88bn | 17.83k | 67.31 | 3.99 | 33.90 | 5.76 | 7.94 | 7.94 | 92.53 | 133.83 | 0.3767 | 2.60 | 4.35 | 372,000.00 | 3.23 | 5.07 | 3.81 | 6.21 | 29.21 | 39.15 | 8.57 | 14.52 | 1.38 | 5.14 | 0.2873 | 30.57 | 7.94 | 3.92 | -46.17 | -0.0306 | 23.95 | 7.78 |
Holder | Shares | % Held |
---|---|---|
Polar Capital LLPas of 19 Oct 2023 | 5.65m | 7.95% |
Fidelity Management & Research Co. LLCas of 31 Jul 2024 | 3.54m | 4.99% |
J.O. Hambro Capital Management Ltd.as of 11 Jan 2024 | 3.13m | 4.41% |
The Vanguard Group, Inc.as of 04 Sep 2024 | 2.49m | 3.51% |
Norges Bank Investment Managementas of 31 Dec 2023 | 1.52m | 2.14% |
Capital Research & Management Co. (World Investors)as of 30 Jun 2024 | 1.48m | 2.09% |
Handelsbanken Fonder ABas of 31 Aug 2024 | 1.18m | 1.67% |
BlackRock Fund Advisorsas of 05 Sep 2024 | 998.28k | 1.41% |
TIAA-CREF Investment Management LLCas of 31 Jul 2024 | 985.65k | 1.39% |
Federated Global Investment Management Corp.as of 30 Jun 2024 | 706.06k | 0.99% |